<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01306825</url>
  </required_header>
  <id_info>
    <org_study_id>4683</org_study_id>
    <nct_id>NCT01306825</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Daptomycin Bone Penetration</brief_title>
  <acronym>DAPTO-HUS</acronym>
  <official_title>Clinical Evaluation of Daptomycin Bone Penetration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bone and joint infections are commonly due to Gram-positive bacteria. Treatment of these&#xD;
      infections is difficult because of the need of prolonged duration of antimicrobial agents in&#xD;
      combination with surgical procedure. Moreover, in recent years, a growing resistance pattern&#xD;
      to various antimicrobial agents has been observed for Gram-positive bacteria. Consequently,&#xD;
      there is an urgent need for new drugs with high bone penetration for the treatment of those&#xD;
      infections. The investigators hypothesized that daptomycin allow to achieve high&#xD;
      concentrations in bone compartments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patients' percentage of which the intra-osseous daptomycin concentration is ≥ 8 times MIC (if available) or ≥ 8 times critical concentration (if Bacteriological documentation is unavailable)</measure>
    <time_frame>5 min before started administration of daptomycin, 5 min after administration of daptomycin and at random after perfusion of daptomycin</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Bone and Joint Infections</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patient under treatment with daptomycin and undergoing imperative surgery with bone&#xD;
        withdrawal&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patient under treatment with daptomycin for more than 3 days with dosage at 6 mg/kg&#xD;
&#xD;
          -  Patient undergoing imperative surgery with bone withdrawal&#xD;
&#xD;
          -  Signed, and dated informed consent as defined by the Institutional Review Board&#xD;
&#xD;
          -  Male and female patients older than 18 years of age&#xD;
&#xD;
          -  Patients with social insurance&#xD;
&#xD;
          -  Patient with information on previous mandatory medical examination&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
          -  Patient with no treatment by daptomycin or with a dosage &lt; 6mg/kg or with less than 3&#xD;
             doses of daptomycine&#xD;
&#xD;
          -  Patient with no need for surgery&#xD;
&#xD;
          -  Patient younger than 18 years of age&#xD;
&#xD;
          -  Pregnant and nursing women&#xD;
&#xD;
          -  Patient refusal for inclusion&#xD;
&#xD;
          -  Patients with deprived liberty&#xD;
&#xD;
          -  Inability to complete the informed consent process because of problems with mental&#xD;
             capacity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Lefebvre, MD</last_name>
    <role>Study Director</role>
    <affiliation>Service des maladies infectieuses et tropicales - Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas Lefebvre, MD</last_name>
    <phone>33 3 69 55 05 45</phone>
    <email>nicolas.lefebvre@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service d'Orthopédie - Hôpital Centre de Chirurgie Orthopédie et de la Main (CCOM) - Hôpitaux Universitaires de Strasbourg - 10 av Achille Baumann -</name>
      <address>
        <city>Illkirch-Graffenstaden</city>
        <zip>67400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannot GAUDIAS, MD</last_name>
      <phone>33 3 88 55 23 45</phone>
      <email>jeannot.gaudias@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Jeannot GAUDIAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cyril BOERI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Plateau Technique de Microbiologie - Hôpitaux Universitaires de Strasbourg - 1, rue Koeberlé</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JEHL François, PHARM D</last_name>
      <phone>33 3 68 85 37 81</phone>
      <email>francois.jehl@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>François JEHL, PARM D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des maladies infectieuses et tropicales - Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Lefebvre, MD</last_name>
      <phone>33 3 69 55 05 45</phone>
      <email>nicolas.lefebvre@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas Lefebvre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel CHRISTMANN Daniel, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yves HANSMANN, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>February 25, 2011</study_first_submitted>
  <study_first_submitted_qc>March 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2011</study_first_posted>
  <last_update_submitted>June 17, 2015</last_update_submitted>
  <last_update_submitted_qc>June 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Daptomycin</keyword>
  <keyword>Bone disease,infectious</keyword>
  <keyword>Osteomyelitis</keyword>
  <keyword>Diabetic foot</keyword>
  <keyword>Staphylococcus aureus</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

